34 results about "DESOXY" patented technology

Conjugates of transferrin, albumin and polyethylence glycol consisting of native or thiolated transferrin or albumin or of polyethylene glycol (MW between approximately 5,000 and 20,0000) with at least one HS-, HO- or H2N group and cytostatic compounds derived through maleinimide or N-hydroxysuccinimide ester compounds, such as doxorubicin, daunorubicin, epirubicin, idarubicin, mitoxandrone, chloroambucil, melphalan, 5-fluorouracyl, 5'-desoxy-5-fluorouridine, thioguanine, methotrexate, paclitaxel, docetaxel, topotecan, 9-aminocamptothecin, etoposide, teniposide, mitopodoside, vinblastine, vincristine, vindesine, vinorelbine or a compound of general formula A, B, C or D, where n=0-6, X=-NH2, -OH, -COOH, -O-CO-R-COR*, -NH-CO-R-COR*, where R is an aliphatic carbon chain with 1-6 carbon atoms or a substituted or unsubstituted phenylene group and R*H, phenyl, alkyl with 1-6 carbon atoms.

The invention relates to an enzyme from Bailing production bacterium Cordyceps Chinese Hirsutella for synthesizing metabolic (desoxy) uridine from (desoxy) cytidine, a gene for coding the enzyme and application thereof. The enzyme is cytidine deaminase which has more than 90% of homology with amino acid sequence disclosed as SEQ ID NO.1; and the coding gene has more than 90% of homology with nucleotide sequence disclosed as SEQ ID NO.2. The invention researches the metabolic pathway of (desoxy) cytidine synthesized (desoxy) uridine in details in principle. The cloned DNA (deoxyribonucleic acid) comprising the nucleotide sequence provided by the invention can be transformed into engineering bacterium by transduction, conversion and conjugal transfer. By adjusting the expression of the (desoxy) uridine biosynthesized gene, the host (desoxy) uridine is endowed with high expressivity, thereby providing an effective way for enhancing the yield of the (desoxy) uridine and having great application prospects.

The invention discloses a synthesis method of 9-desoxy-9-homoerythromycin A(Z) oxime, which comprises the following steps: adding 9-desoxy-9-homoerythromycin A(E) oxime into an organic solvent, wherein the mass-volume ratio of the 9-desoxy-9-homoerythromycin A(E) oxime to the organic solvent is 1g:(3-10)ml; stirring until the 9-desoxy-9-homoerythromycin A(E) oxime is completely dissolved, and adding an alkali, wherein the mole ratio of the 9-desoxy-9-homoerythromycin A(E) oxime to the alkali is 1:(0.2-1.0); stirring at 0-5 DEG C for 64-82 hours; and after the reaction finishes, filtering, washing the obtained filter residue with a 0-5-DEG C organic solvent to obtain a white solid, and carrying out vacuum drying on the white solid to obtain the 9-desoxy-9-homoerythromycin A(Z) oxime finished product. The method is very simple in technical process and very convenient to operate. The synthesized 9-desoxy-9-homoerythromycin A(Z) oxime has the advantages of high purity, no color change and high yield.

The invention relates to a method for preparing 2-C-methyl-D-ribotide-1,4-lactone, which comprises the following steps: adding a raw material D-glucose into dibenzyl amine, acetic acid and ethanol at room temperature, dissolving by stirring, heating, and refluxing to generate 1-desoxy-1-(N,N-amino)-D-fructose; after finishing the reaction, cooling to room temperature to obtain a white solid, drying to obtain 1-desoxy-1-(N,N-amino)-D-fructose, dissolving the 1-desoxy-1-(N,N-amino)-D-fructose and CaO in ethanol and water by stirring, and heating under reflux; and after finishing the reaction, cooling, carrying out centrifugal drying to remove the solvent, adding water and oxalic acid hydrate to precipitate abundant calcium oxalate, filtering, washing, carrying out centrifugal drying on the filtrate to obtain a black viscous liquid, adding acetone, cooling by standing, and recrystallizing with acetone to obtain the 2-C-methyl-D-ribotide-1,4-lactone. The method has the advantages of reasonable technique, low cost, short reaction time and high yield, and is simple to operate.

The invention discloses a specificity monoclonal antibody capable of distinguishing various carbadox and cyadox metabolism products and an enzyme linked immunosorbent assay method and kit for detecting the carbadox and cyadox metabolism products. According to the invention, the monoclonal antibody is secreted by a hybridoma cell strain DCBX5B1 of which the preservation number is CCTCC NO: C201495. Compared with the prior art, the monoclonal antibody disclosed by the invention can distinguish DCBX, bisdesoxy cyadox and desoxy cyadox (N4) at the same time, and has higher sensitivity and specificity. The ELISA method and the kit, disclosed by the invention, can detect the residue of the carbadox and cyadox metabolism products in meat food at the same time, and have the advantages of high detection efficiency, high sensitivity, high precision, high accuracy and the like.

The invention discloses novel N-4-phenylsulfonamido--N'-1-desoxy-(2-desoxy-2-substituted-amino)-beta-D-glucopyransoylthiocarbamide compounds with the general formula disclosed in the specification, which have the activity of inhibiting carbonic anhydrase and further achieve the effect of resisting tumor metastasis and invasion. The compounds structurally have the three active segments sulfamine, substituted glucosamine and thiocarbamide, and the three active segments and Zn<2+> ions in the carbonic anhydrase form coordinate bonds, thereby inhibiting the catalytic activity of the enzyme and performing the function of resisting tumor metastasis and invasion. Thus, the compounds have application potential in the aspect of antitumor drugs. In the general formula, R is defined in the specification.

The invention belongs to the technical field of chemical medicines, and particularly relates to a Beta-L-2'-desoxy-thymine nucleoside derivative, a preparation method and purposes thereof. The Beta-L-2'-desoxy-thymine nucleoside derivative has a structure as showed in a format I, wherein R1 and R2 are independent O, S or Se; when one of the R1 and the R2 is O, R3 is halogen, -OH, -NH2, C1-C8 alkyl, (CH2)nF, (CH2)n-1CHF or CF3; R4 is halogen, H, or CF3; and n is 1-8. The invention provides the derivative which has activity of resisting hepatitis virus, and offers a new choice for preparing medicines capable of treating the hepatitis.

This invention discloses 3-desoxy-2-methylene-19-nor-vitamin D analogs, and specifically (20S)-3-desoxy-2-methylene-1α,25-dihydroxy-19-nor-vitamin D3 and (20R)-3-desoxy-2-methylene-1α,25-dihydroxy-19-nor-vitamin D3 as well as pharmaceutical uses therefor. These compounds exhibit relatively high binding activity and pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to monocytes thus evidencing use as anti-cancer agents especially for the treatment or prevention of osteosarcoma, leukemia, colon cancer, breast cancer, skin cancer or prostate cancer. These compounds also exhibit relatively high calcemic activity evidencing use in the treatment of bone diseases.

This invention discloses 1-desoxy-2-methylene-19-nor-vitamin D analogs, and specifically (20S)-25-hydroxy-1-desoxy-2-methylene-19-nor-vitamin D3 and pharmaceutical uses therefor. This compound exhibits relatively high binding activity and pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent especially for the treatment or prevention of leukemia, colon cancer, breast cancer, skin cancer or prostate cancer.